Skip to content

Efficacy of Cortone injection on frozen shoulder

Comparison of therapeutic outcomes of intra-articular injection of Betamethasone and Methylprednisolone in frozen shoulder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180423039388N1
Enrollment
72
Registered
2024-04-21
Start date
2024-01-21
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

frozen shoulder (adhesive capsulitis). Adhesive capsulitis of shoulder

Interventions

Intervention 1: 1st Intervention group: single dose of intra-articular injection of 1cc(40mg)Methylprednisolone mixed with 3cc lidocaine 2%. Intervention 2: 2nd Intervention group: single dose of intr

Sponsors

deputy of research - Iran university of medical science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients with ages between 18 and 80 active and passive restriction of shoulder range of motion (forward flexion less than 100 degrees, external rotation less than 30 degrees, internal rotation less than L1 vertebra, Stage 2 or 3 adhesive capsulitis according to the classification of Hannafin and Chiaia complaint of pain for 1month at least and of ROM restriction for 3 months at least written consent of participation in study

Exclusion criteria

Exclusion criteria: shoulder corticosteroids injection in last 6 months chronic long-term use of oral corticosteroids or in last 2 weeks history of shoulder surgery, shoulder fracture, shoulder dislocation in last 3 months shoulder septic or inflammatory arthritis or any evidence in favor of shoulder cellulitis uncontrolled Diabetes (HbA1C more than 7%, injection day BS more than 300) cuff full thickness tear or cuff partial thickness tear more than 50% in shoulder MRI Calcium deposition or Glenohumeral Osteoarthritis in shoulder AP and Axillary Xray neuromuscular diseases, systemic skeletal diseases, skeletal or soft tissue cancers of shoulder or organs around the shoulder use of Warfarin, Rivaroxaban, Apixaban, or any evidence in favor of bleeding susceptibility (INR>2, aptt>80 sec, platelet< 50000)

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: before injection and 1, 3 , 6 months after injection. Method of measurement: visual analog scale.;Shoulder range of motion. Timepoint: before injection and 1, 3 , 6 months after injection. Method of measurement: exam with goniometer.;Shoulder and pain disability. Timepoint: before injection and 6 months after injection. Method of measurement: SPADI questionnaire(Shoulder Pain And Disability Index).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Sobhani Eraghi

Iran University of Medical Sciences

sobhani.a@iums.ac.ir+98 21 6435 1111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026